HILLSIDE, N.J., Dec. 6 /PRNewswire-FirstCall/ -- INB:Biotechnologies Inc., a wholly owned biotech subsidiary of Integrated BioPharma, Inc. , and City of Hope Cancer Center have entered into a collaboration research and development agreement to carry out a phase I human clinical trial. The study will examine INB’s proprietary plant-derived oral formulation of selenium, Phytosel(R), to determine whether the side effects of two chemotherapeutic drugs can be lowered with high doses of Phytosel(R). The study is expected to start in early 2006 and will take approximately one year to complete.
“If chemotherapy side effects such as mucositis, diarrhea or lowering of blood counts can be reduced, higher and more consistent chemotherapy doses could be given. This could result in greater treatment efficacy,” said Stephen Shibata, M.D., principal investigator for the study at City of Hope.
The micronutrient consists of organic selenium compounds that are produced in hydroponically grown Indian mustard plants using a hyperaccumulation production process.
E. Gerald Kay, chief executive officer of INB, said, “We are very pleased to have the opportunity to work with City of Hope on a program that can help cancer patients. Our proprietary selenium product, Phytosel(R), developed with funding from the National Institutes of Health, offers the potential to lower the side effects of chemotherapeutic drugs that can be so severe that the patient cannot tolerate the drug itself, which often is a life-and-death situation for the patient.”
About City of Hope
City of Hope is one of the world’s leading research and treatment centers for cancer, diabetes, HIV/AIDS and other life-threatening diseases. Named by U.S.News & World Report as one of America’s best medical centers for cancer treatment, City of Hope is a Comprehensive Cancer Center, the highest designation bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics.
City of Hope’s scientific knowledge is shared with medical centers locally and globally, helping patients battling life-threatening diseases. For more information, visit www.cityofhope.org.
About Integrated BioPharma Inc (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company’s financial results can be found in the company’s Reports filed with the Securities and Exchange Commission.
Contact: Dina Masi, CFO Integrated BioPharma Inc 888-319-6962 d.masi@ibiopharma.com
Integrated BioPharma, Inc.
CONTACT: Dina Masi, CFO of Integrated BioPharma, Inc., +1-888-319-6962,d.masi@ibiopharma.com
